Navigation Links
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
Date:8/30/2012

SAN DIEGO, Aug. 30, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present corporate updates at the following three upcoming investor conferences:

  • Stifel Nicolaus Healthcare Conference
    Presentation: September 6, 2012, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time) at the Four Seasons Hotel in Boston, Massachusetts
    Presenting: Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer 
  • NewsMakers in the Biotech Industry
    Presentation: September 7, 2012, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time) at the Millennium Broadway Hotel in New York, New York
    Presenting: Craig M. Audet, Senior Vice President, Operations and Head of Global Regulatory Affairs
  • Bank of America Merrill Lynch Global Healthcare Conference
    Presentation: September 12, 2012, at 8:55 a.m. British Summer Time (12:55 a.m. Pacific Time) at the Bank of America Merrill Lynch Financial Centre in London, England
    Presenting: Dominic P. Behan, Ph.D., Executive Vice President and Chief Scientific Officer 
  • Arena's presentations at these conferences will be webcast live. Each of the audio webcasts will be available under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the presentation. Please connect to Arena's website several minutes prior to the start of each webcast to ensure adequate time for any software download that may be necessary. 

    Arena also announced today that it is scheduled to participate in panel presentations at Citi's 7th Annual Biotech Day on September 5, 2012, at the Mandarin Oriental Hotel in Boston, Massachusetts and at the Rodman and Renshaw Global Investment Conference on September 10, 2012, at The Waldorf Astoria Hotel in New York, New York. These panel presentations will not be webcast.About Arena Pharmaceuticals
    Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information about Arena, please visit www.arenapharm.com.

    Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.

    Forward-Looking Statements
    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's efforts, focus, goals, strategy, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from lorcaserin, including the timing and impact of competition; the timing and outcome of regulatory review is uncertain; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; the entry into, modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review, approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

     Contact: Arena Pharmaceuticals, Inc.

    Media Contact: Russo PartnersCindy McGee, Vice President,

    David Schull, PresidentInvestor Relations & Alliance Management

    david.schull@russopartnersllc.comcmcgee@arenapharm.com

    858.717.2310858.453.7200, ext. 1479 www.arenapharm.com 
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
    2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
    3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
    4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
    5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
    6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
    7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
    8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
    9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
    10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
    (Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
    (Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
    Breaking Medicine Technology:
    (Date:4/30/2017)... Viejo, CA (PRWEB) , ... April 30, 2017 ... ... animations created exclusively for use in Final Cut Pro X. Editors can pick ... and more. Easily change the highlights, mid levels and shadows using simple color ...
    (Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of ... video to the next without having to set a single keyframe in Final ... enhance your video production. , TransDark features dynamic transitions that momentarily splits the RGB ...
    (Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty ... pounds with the help of a weight loss surgery. The woman, declaring “I will not ... have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while ...
    (Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
    (Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
    Breaking Medicine News(10 mins):